GSK plc (NYSE:GSK) Shares Sold by Signaturefd LLC

Signaturefd LLC trimmed its stake in shares of GSK plc (NYSE:GSK) by 5.1% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 32,055 shares of the pharmaceutical company’s stock after selling 1,705 shares during the quarter. Signaturefd LLC’s holdings in GSK were worth $1,310,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the stock. Sequoia Financial Advisors LLC boosted its holdings in GSK by 2.6% in the 3rd quarter. Sequoia Financial Advisors LLC now owns 22,937 shares of the pharmaceutical company’s stock worth $938,000 after buying an additional 577 shares during the last quarter. Foundations Investment Advisors LLC lifted its position in shares of GSK by 4.8% in the third quarter. Foundations Investment Advisors LLC now owns 10,122 shares of the pharmaceutical company’s stock valued at $414,000 after acquiring an additional 466 shares in the last quarter. Ledyard National Bank boosted its stake in shares of GSK by 24.1% in the third quarter. Ledyard National Bank now owns 24,281 shares of the pharmaceutical company’s stock worth $993,000 after acquiring an additional 4,712 shares during the last quarter. Allspring Global Investments Holdings LLC increased its position in shares of GSK by 40.7% during the third quarter. Allspring Global Investments Holdings LLC now owns 11,764 shares of the pharmaceutical company’s stock worth $481,000 after purchasing an additional 3,405 shares in the last quarter. Finally, Blue Trust Inc. raised its stake in GSK by 335.1% in the 3rd quarter. Blue Trust Inc. now owns 10,720 shares of the pharmaceutical company’s stock valued at $413,000 after purchasing an additional 8,256 shares during the last quarter. Institutional investors and hedge funds own 15.74% of the company’s stock.

GSK Price Performance

Shares of GSK stock opened at $37.96 on Thursday. The company has a debt-to-equity ratio of 0.99, a current ratio of 0.82 and a quick ratio of 0.54. The company has a market capitalization of $78.67 billion, a PE ratio of 13.75, a price-to-earnings-growth ratio of 1.30 and a beta of 0.65. The firm’s 50-day moving average is $41.27 and its two-hundred day moving average is $41.19. GSK plc has a 12 month low of $33.67 and a 12 month high of $45.92.

GSK (NYSE:GSK) last announced its quarterly earnings results on Wednesday, July 31st. The pharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.00 by $0.09. GSK had a net margin of 12.87% and a return on equity of 51.48%. The business had revenue of $9.95 billion during the quarter, compared to the consensus estimate of $9.49 billion. Analysts predict that GSK plc will post 4.14 earnings per share for the current year.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, October 10th. Stockholders of record on Friday, August 16th were paid a $0.3843 dividend. This represents a $1.54 annualized dividend and a dividend yield of 4.05%. The ex-dividend date was Friday, August 16th. This is a positive change from GSK’s previous quarterly dividend of $0.38. GSK’s dividend payout ratio is 55.80%.

Insider Transactions at GSK

In related news, major shareholder Plc Gsk bought 2,791,930 shares of the firm’s stock in a transaction on Friday, September 27th. The shares were bought at an average price of $8.00 per share, with a total value of $22,335,440.00. Following the completion of the transaction, the insider now directly owns 16,775,691 shares of the company’s stock, valued at $134,205,528. This represents a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 10.00% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. Argus raised shares of GSK to a “strong-buy” rating in a research note on Wednesday, August 7th. UBS Group cut shares of GSK from a “buy” rating to a “neutral” rating in a research note on Monday, July 8th. Jefferies Financial Group increased their price objective on shares of GSK from $52.50 to $53.00 and gave the company a “buy” rating in a report on Tuesday, July 2nd. Finally, Barclays upgraded GSK to a “hold” rating in a report on Tuesday, August 27th. Four investment analysts have rated the stock with a hold rating, two have given a buy rating and four have given a strong buy rating to the stock. According to data from MarketBeat.com, GSK presently has an average rating of “Buy” and an average target price of $50.00.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.